| Revenue Growth | Yard-Temlia gross sales $41.8M (up 30%); net sales $35.9M (up 26%). |
|---|---|
| Mgmt Confidence | High confidence in US launch momentum; disappointed by 'misguided' European CHMP decision. |
| Demand Visibility | Unique ordering accounts increased 49% to 109; P&T approvals at 80% top-centers. |
| Margin Trends | Gross-to-net deductions increased to 14% from 11.5% due to 340B utilization. |
| Op. Leverage | Second consecutive quarter of positive operating cash flow at $13.3M. |
| Pricing Power | Yard-Temlia holds pass-through status through June 2029, exempting it from 340B cuts. |
| Vol vs Price | Growth driven by increased adult adoption (70% mix) and outpatient utilization. |
| Segment Growth | Adult patients now 70% of utilization; pediatric patients 30%. |
| New Clients | Added 36 unique ordering accounts this quarter; total now 109. |
| Capex & Debt | Repurchased $30.5M of 2029 notes; reduced outstanding principal by 43%. |
| Regulatory | CHMP issued negative opinion in EU; closing compassionate use program there. |
| Commentary | Strategic focus on educating nurses and nephrologists to drive earlier TATMA identification. |
| New Launches | Launched Yard-Temlia late January 2026; NTAP reimbursement effective October 1, 2026. |
Growth
Net sales grew 26% quarter-over-quarter; non-GAAP net income rose 161% to $4.7M.
Outlook
Expects higher Q4 operating expenses; targeting first-in-human AML trial for late 2027.
Risks
Management pivoted to vague language when asked for 2027 guidance and specific vial volume splits.
The company's earnings call, NASDAQ: OMER, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Omeros Corporation: key numbers
- Share price
- $16.68Close, Nov 16
- Market cap
- $1.24B
- Shares outstanding
- 74.46MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Omeros Corporation
All →Omeros Financial Results
Omeros Corporation reported Q3 2026 financial results, highlighted by a 26% sequential increase in net revenue for YARTEMLEA to $35.9 million. The company reported a GAAP net loss of $57.4 million, primarily driven by a $62.0 million non-cash mark-to-market adjustment on convertible notes, while achieving positive operating cash flow of $13.3 million.
- Term
- Q3 2026
“YARTEMLEA sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow. As expected, 340B participation increased, reflecting substantial expansion of our customer base and increased outpatient use of YARTEMLEA. That momentum has continued into the fourth quarter, with YARTEMLEA revenues continuing to grow.”
Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer
Omeros Stock Plan Amendment
Omeros Corporation granted a performance-based stock option award to CEO Gregory A. Demopulos for up to 500,000 shares at an exercise price of $17.88. The award vests across four tranches tied to stock-price hurdles ranging from $25.00 to $40.00 per share and requires continued service over a four-year period. The grant is intended to incentivize long-term shareholder value creation following the company's recent strategic milestones, including FDA approval of YARTEMLEA.
- Term
- 5 years
Omeros VP, Finance & CAO David J. Borges Sells $419K of Stock
David J. Borges, VP, Finance & CAO, sold 20,000 shares of Omeros Corp at $20.95 a share, worth $419K in total between Sep 22, 2026 and Sep 23, 2026. Shares held after the trade: 0 (-100.0%).
- Value
- $419K
- Shares
- 20,000
- Average price
- $20.95
- Role
- VP, Finance & CAO
- Holding change
- -100.0%
- Trade date
- Sep 22, 2026 to Sep 23, 2026